Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of JMKX003142 in Healthy Participants
NCT07565441Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JMKX003142 in autosomal dominant polycystic kidney disease (ADPKD) (5 cohorts), sponsored by Jemincare. Primary endpoints: Maximum Plasma Concentration at 144 hours and Area Under the Curve at 144 hours. Planned start May 2026; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07565441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565441.